Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease.
作者信息
Heneghan Carl
机构信息
Centre for Evidence-Based Medicine & Dept of Primary Health Care, University of Oxford.
出版信息
Cochrane Database Syst Rev. 2011 Jan 14;2011(8):ED000017. doi: 10.1002/14651858.ED000017.
Abstract
摘要
相似文献
1
Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease.心血管疾病一级预防的证据仍存在相当大的不确定性。
Cochrane Database Syst Rev. 2011 Jan 14;2011(8):ED000017. doi: 10.1002/14651858.ED000017.
2
Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease.
Cochrane Database Syst Rev. 2011 Jan 14(8):ED000018. doi: 10.1002/14651858.ED000018.
3
A systematic review and economic evaluation of statins for the prevention of coronary events.他汀类药物预防冠状动脉事件的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.
4
Are statins indicated for the primary prevention of CAD in octogenarians? antagonist viewpoint.
Am J Geriatr Cardiol. 2003 Nov-Dec;12(6):357-60. doi: 10.1111/j.1076-7460.2003.02912.x.
5
Cholesterol confusion in primary prevention of coronary artery disease.冠状动脉疾病一级预防中的胆固醇困惑
Cardiovasc Drugs Ther. 1993 Nov;7(5):779-84. doi: 10.1007/BF00878930.
6
Lipid-lowering for prevention of coronary heart disease: what policy now?降低血脂以预防冠心病：现在该采取什么政策？
Clin Sci (Lond). 1996 Oct;91(4):399-413. doi: 10.1042/cs0910399.
7
[Primary prevention of coronary heart disease: possibilities and limitations].
Schweiz Rundsch Med Prax. 1990 Sep 11;79(37):1050-4.
8
Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.他汀类药物在冠心病和缺血性中风一级及二级预防中的应用。随机试验的荟萃分析。
Int J Clin Pharmacol Ther. 2003 Dec;41(12):567-77. doi: 10.5414/cpp41567.
9
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.阿司匹林用于冠心病一级预防：基于随机试验荟萃分析得出的与冠脉风险相关的安全性及绝对获益
Heart. 2001 Mar;85(3):265-71. doi: 10.1136/heart.85.3.265.
10
In people with no evidence of cardiovascular disease, how effective are interventions aimed at controlling risk factors in reducing all-cause and coronary artery disease mortality?在没有心血管疾病证据的人群中，旨在控制风险因素的干预措施在降低全因死亡率和冠状动脉疾病死亡率方面的效果如何？
West J Med. 2000 Sep;173(3):185-6. doi: 10.1136/ewjm.173.3.185.
引用本文的文献
1
Policy, Research and Residents' Perspectives on Built Environments Implicated in Heart Disease: A Concept Mapping Approach.政策、研究与居民对与心脏病相关的建筑环境的看法：一种概念映射方法。
Int J Environ Res Public Health. 2017 Feb 9;14(2):170. doi: 10.3390/ijerph14020170.
2
Statins: Can we advocate them for primary prevention of heart disease?他汀类药物：我们能提倡将它们用于心脏病的一级预防吗？
Med J Armed Forces India. 2014 Jul;70(3):270-3. doi: 10.1016/j.mjafi.2013.05.008. Epub 2013 Aug 30.
3
Lipid patterns, alcohol intake and BMI of adult Nigerians in a sub-urban slum in Enugu, Nigeria.尼日利亚埃努古一个城郊贫民窟中成年尼日利亚人的血脂模式、酒精摄入量和体重指数
Pan Afr Med J. 2014 May 10;18:37. doi: 10.11604/pamj.2014.18.37.1926. eCollection 2014.
4
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.冠心病的一级预防：新数据整合、观点演变、目标修订以及瑞舒伐他汀在管理中的作用。一项全面综述。
Drug Des Devel Ther. 2011;5:325-80. doi: 10.2147/DDDT.S14934. Epub 2011 Jun 13.
本文引用的文献
1
Statins for the primary prevention of cardiovascular disease.他汀类药物用于心血管疾病的一级预防。
Cochrane Database Syst Rev. 2011 Jan 19(1):CD004816. doi: 10.1002/14651858.CD004816.pub4.
2
Multiple risk factor interventions for primary prevention of coronary heart disease.用于冠心病一级预防的多重危险因素干预措施。
Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD001561. doi: 10.1002/14651858.CD001561.pub3.
3
Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".沃斯等人就文章《他汀类药物用于高敏C反应蛋白升高或血脂异常女性心血管事件一级预防：来自他汀类药物在预防中的应用理由：一项评估瑞舒伐他汀的干预试验（JUPITER）及一级预防试验女性荟萃分析的结果》所写的信。
Circulation. 2010 Dec 7;122(23):e576; author reply e577. doi: 10.1161/CIRCULATIONAHA.110.954016.
4
What are the basic self-monitoring components for cardiovascular risk management?心血管风险管理的基本自我监测内容有哪些？
BMC Med Res Methodol. 2010 Nov 12;10:105. doi: 10.1186/1471-2288-10-105.
5
Optimal cardiovascular prevention strategies for the 21st century.21世纪的最佳心血管预防策略。
JAMA. 2010 Nov 10;304(18):2057-8. doi: 10.1001/jama.2010.1641.
6
Will cardiovascular disease prevention widen health inequalities?心血管疾病预防会扩大健康不平等吗？
PLoS Med. 2010 Aug 24;7(8):e1000320. doi: 10.1371/journal.pmed.1000320.
7
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.他汀类药物对无心血管疾病但有心血管危险因素人群的益处：随机对照试验的荟萃分析。
BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376.
8
Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis.他汀类药物治疗在冠心病一级预防中的性别影响：一项荟萃分析。
Int J Cardiol. 2010 Jan 7;138(1):25-31. doi: 10.1016/j.ijcard.2008.08.001. Epub 2008 Sep 14.
9
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).欧洲临床实践中心血管疾病预防指南：全文。欧洲心脏病学会及其他学会关于临床实践中心血管疾病预防的第四联合工作组（由九个学会的代表及特邀专家组成）。
Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113. doi: 10.1097/01.hjr.0000277983.23934.c9.
10
Questioning the benefits of statins.质疑他汀类药物的益处。
CMAJ. 2005 Nov 8;173(10):1207; author reply 1210. doi: 10.1503/cmaj.1050120.
Zotero 插件